A call for the comprehensive diagnosis of viral hepatitis as a key step towards its elimination
Javier Crespo, José Luís Calleja, Joaquín Cabezas, Féderico García, Antonio Aguilera, Francisco Jorquera, Jeffrey V. Lazarus
Abstract
Javier Crespo: reports consultant and/or speaker and/or participated in clinical trials sponsored and/or received grants and research support from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc, Celgene and Alexion (all outside the submitted work). Jose Luis Calleja: Consultant and Lectures: Gilead Sciences, Abbvie, Roche, Intercept, MSD. Joaquín Cabezas: receives grants from Gilead and Abbvie; lectures: Gilead and Abbvie. Federico García: declares that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Antonio Aguilera: has nothing to disclose. Francisco Jorquera: declares personal fees from AbbVie and Gilead Sciences, and advisory and personal fees from Intercept. Jeffrey V Lazarus: has received grants to his institution from AbbVie, Gilead Sciences and MSD, and personal fees from AbbVie, Gilead Sciences, Intercept Pharmaceuticals, Janssen Pharmaceuticals, MSD, Novo Nordisk, Roche, outside of the submitted work.